参佛胃康治疗慢性萎缩性胃炎胃癌前病变作用机制研究  

Study on the Mechansim of Shenfo Weikang in the Treatment of Precancerous Lesions of Gastric Cancer:Chronic Atrophic Gastritis

作　　者：李盟 赵迪 杜燕青 李特 蔺焕萍[1] 周小燕 LI Meng;ZHAO Di;DU Yanqing;LI Te;LIN Huanping;ZHOU Xiaoyan(Shaanxi University of Chinese Medicine,Xianyang 712046,China;Huzhou Hospital of Traditional Chinese Medicine,Huzhou 313000,China;Xi'an No.9 Hospital,Xi'an 710054,China;Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712000,China)

机构地区：[1]陕西中医药大学,陕西咸阳712046 [2]湖州市中医院,浙江湖州313000 [3]西安市第九医院,陕西西安710054 [4]陕西中医药大学附属医院,陕西咸阳712000

出　　处：《西部中医药》2024年第9期30-34,共5页Western Journal of Traditional Chinese Medicine

基　　金：陕西省科技厅科研项目(2022JM-465);陕西省中医药管理局中医药科研课题(JCPT004);陕西中医药大学校级科研课题(2016QN07);咸阳市科技局科研课题(2018KT-42)。

摘　　要：目的:探讨参佛胃康治疗慢性萎缩性胃炎胃癌前病变的作用机制。方法:利用Wistar大鼠制备胃癌前病变模型,空白组6只不造模,其余大鼠通过综合性N-甲基-N'-硝基-N-亚硝基胍(1-Methyl-3-nitro-1-nitrosoguanidine,MNNG)复合造模方法制备胃癌前病变模型,将建模成功的大鼠随机分为模型组、参佛胃康组、丽珠得乐组,空白组及模型组灌胃生理盐水,参佛胃康组及丽珠得乐组予相应剂量参佛胃康1.22 g/(kg·d)和丽珠得乐0.18 g/(kg·d),各组均干预4周。干预结束后,观察各组大鼠一般情况;苏木素-伊红(hematoxylin-eosin,HE)染色观察大鼠胃组织病理学变化情况;Western Blot法检测胃黏膜组织中磷脂酰肌醇3-激酶/蛋白激酶B(phosphatidylinositol 3-kinase/protein kinase B,PI3K/Akt)信号通路相关蛋白及B细胞淋巴瘤2(B cell lymphoma-2 protein,Bcl-2)蛋白表达水平。结果:参佛胃康组大鼠毛色、精神状况、体质量、食欲、大便等一般情况优于模型组。与模型组比较,丽珠得乐组大鼠胃黏膜腺体数量减少,排列欠规则,但炎性细胞浸润程度较模型组轻,部分区域可见充血、水肿以及淋巴细胞聚集;参佛胃康组大鼠胃黏膜上皮相对完整,细胞形态相对均匀,腺体数量较多,分布排列相对整齐且规则。与模型组比较,丽珠得乐组和参佛胃康组Bcl-2蛋白的相对表达降低,p-PI3K/PI3K、p-Akt/Akt比例均降低(P<0.05),参佛胃康组低于丽珠得乐组(P<0.05)。结论:参佛胃康能够改善慢性萎缩性胃炎胃癌前病变大鼠一般情况及其胃黏膜病理状态,其作用机制可能与参佛胃康调控PI3K/Akt信号通路,抑制PI3K、Akt、Bcl-2蛋白表达,影响细胞凋亡有关。Objective:To discuss the mechanism of Shenfo Weikang in the treatment of precancerous lesions of gastric cancer(PLGC)in chronic atrophic gastritis(CAG)patients.Methods:Wistar rats were utilized to establish PLGC models,six rats in the blank group remained unhandled,other rats were prepared into PLGC models by MNNG,after successfully modeling,the rats were randomized into the model group,Shenfo Weikang group and colloidal bismuth subcitrate capsules group,the blank group and the model group accepted intragastric administration of physiological saline,Shenfo Weikang group and colloidal bismuth subcitrate capsules group were given the corresponding dosages of Shenfo Weikang,1.22 g/(kg·d),and colloidal bismuth subcitrate capsules,0.18 g/(kg·d),all the groups were intervened for four weeks.By the end of intervention,to observe the general conditions of the rats in different groups;HE staining was used to observe pathological changes of the stomach in the rats;western blot(WB)was applied to detect the expressions of PI3l/Akt signaling pathway and Bcl-2 protein in gastric mucosa.Results:The general conditions including coat colour,mental state,body mass,appetite,defecation and others of Shenfo Weikang were superior to these of the model group.Compared with the model group,the number of glands in gastric mucosa decreased and arranged less regularly in colloidal bismuth subcitrate capsules group,but the degree of inflammatory cell infiltration was milder than that in the model group,and congestion,edema,and lymphocyte accumulation were observed in some areas;the gastric mucosal epithelium is relatively intact,with a relatively uniform cell morphology,a large number of glands,arranged in a relatively orderly and regular pattern.Compared with the model group,the relative expressions of Bcl-2 reduced in colloidal bismuth sublitrate capsules group,and shenfo weikang group.The ratios of p-PI3K/PI3K,p-Akt/Akt reduced in colloidal bismuth subcitrate capsules group and ShenfoWeikang group(P<0.05),Shenfo Weikang group was lower

关 键 词：萎缩性胃炎 胃癌前病变 磷脂酰肌醇3-激酶/蛋白激酶B B细胞淋巴瘤-2蛋白 信号通路 参佛胃康 丽珠得乐 

分 类 号：R256.39[医药卫生—中医内科学]